Dr. Cooper studies molecular and genetic changes underlying liver diseases including
hepatitis B and C, and he uses genomic and proteomic approaches to uncover new therapeutic
targets for the hepatitis virus. Current research in the Cooper lab includes investigations
of how natural killer cells, T cells, and hybrid natural killer T cells may interact
to clear hepatitis C, and how related sets of genes influence immune response. Dr.
Cooper directs the Kalmanovitz Liver Immunology Laboratory at CPMC, and leads translational
research to identify immunological influences on disease outcomes in patients with
hepatitis C (including those undergoing liver transplantation). Under Dr. Cooper’s
leadership, validated biomarkers for liver and biliary diseases will be used to personalize
treatment and help predict an individual’s response to therapy.
California Pacific Medical Center Research Institute
2340 Clay Street, 3rd Floor
San Francisco, CA, 94115
(415) 600-1020
scooper@cpmcri.org